# Aerobic exercise facilitates p300 nuclear translocation via ADRB2-AMPKα signaling, leading to enhanced histone acetylation and mitigation of cognitive decline in APP/PS1 mice

**Authors:** Gao-shang Chai, Tian-long Gao, Shu-guang Bi, Yu-ming Mao, Liu Yang, Fang-zhou Wang, Jia Chen, Jia-jun Wu, Juan Gong, Shan Geng, Jia-qi Yuan, Ke-yu Zhang, Hai-yan Yi, Zi-chong Lan, Yun-juan Nie, Haitao Yu

PMC · DOI: 10.1186/s13195-026-01983-z · Alzheimer's Research & Therapy · 2026-02-10

## TL;DR

Aerobic exercise helps protect against Alzheimer's by improving brain cell function through a specific molecular pathway involving p300 and AMPKα.

## Contribution

The study identifies a novel ADRB2-AMPKα-p300 signaling axis linking aerobic exercise to epigenetic changes that mitigate cognitive decline.

## Key findings

- Aerobic exercise reduced Aβ pathology and cognitive deficits in APP/PS1 mice.
- AE activated ADRB2, leading to AMPKα phosphorylation and p300 nuclear translocation.
- AMPKα inhibition reversed the beneficial effects of exercise on synaptic plasticity and p300 translocation.

## Abstract

Physical activity (PA) is strongly associated with enhanced cognitive resilience and a lower risk of Alzheimer’s disease (AD) in the aging population. However, the molecular mechanisms linking exercise-induced neuroprotection to epigenetic remodeling remain poorly defined.

A total of 1,511 participants from the National Health and Nutrition Examination Survey (NHANES) 2013–2014 cohort were included to assess the association between PA and cognitive performance. Mendelian randomization (MR) analysis was further employed to infer the causal relationship between PA and the risk of various dementias. Differential gene enrichment analysis was performed using the Gene Expression Omnibus (GEO) dataset (GSE110298) to compare transcriptomic profiles between sedentary and high PA groups in patients with AD. For mechanistic exploration, APP/PS1 transgenic mice underwent an 8-week treadmill-based aerobic exercise (AE) intervention (5 days/week, 40 min/day), followed by comprehensive assessments, including behavioral tests, pathological examinations, epigenetic and molecular biological analyses, and single-cell RNA sequencing.

Epidemiological analysis of the NHANES cohort revealed a nonlinear, dose-dependent relationship between PA and cognitive performance. MR supported a causal effect of genetically predicted higher PA on reduced AD risk. Transcriptomic profiling from GEO identified synaptic signaling and neurogenesis as key pathways modulated by exercise. In APP/PS1 mice, AE alleviated Aβ pathology and cognitive deficits, restored synaptic plasticity, and normalized synaptic protein expression. Mechanistically, AE activated ADRB2, triggering AMPKα phosphorylation and its interaction with the N-terminal (1–200 aa) region of p300. This interaction facilitated p300 nuclear translocation and subsequent enhanced histone H4K5 and H4K12 acetylation, promoting synaptic gene (e.g., GluN1) transcription. The AE-induced nuclear translocation of p300 and the improved synaptic plasticity in APP/PS1 mice were abolished by AMPKα inhibition with dorsomorphin (AMPK inhibitor, 10 mg/kg, intraperitoneal injection).

These findings unveil a previously unrecognized ADRB2-p-AMPKα-p300 axis that AE utilizes to orchestrate chromatin remodeling, counteracting synaptic degeneration and cognitive decline in AD, providing actionable targets for exercise-mimetic therapies.

The online version contains supplementary material available at 10.1186/s13195-026-01983-z.

## Linked entities

- **Genes:** ADRB2 (adrenoceptor beta 2) [NCBI Gene 154], EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033], GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 2902]
- **Proteins:** EP300 (EP300 lysine acetyltransferase)
- **Chemicals:** dorsomorphin (PubChem CID 11524144)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, Adrb2 (adrenergic receptor, beta 2) [NCBI Gene 11555] {aka Adrb-2, Badm, Gpcr7}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, Ep300 (E1A binding protein p300) [NCBI Gene 328572] {aka A430090G16, A730011L11, KAT3B, p300, p300 HAT}
- **Diseases:** dementias (MESH:D003704), synaptic degeneration (MESH:D012183), AD (MESH:D000544), cognitive decline (MESH:D003072)
- **Chemicals:** dorsomorphin (MESH:C516138)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990585/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990585/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990585/full.md

---
Source: https://tomesphere.com/paper/PMC12990585